{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T13:08:45Z","timestamp":1793452125353,"version":"4.5.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T00:00:00Z","timestamp":1763424000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T00:00:00Z","timestamp":1763424000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002352","name":"Ain Shams University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002352","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Drugs Ther"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Emerging lipid-lowering therapies, such as Plozasiran, target apolipoprotein C-III (APOC-III) by inhibiting its hepatic production at the mRNA level, presenting a novel approach to lipid regulation. However, the safety and efficacy of plozasiran have yet to be fully established.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We searched PubMed, Scopus, Web of Science, and Cochrane CENTRAL register of trials for studies comparing plozasiran to placebo in patients with dyslipidemic disorders. The primary outcomes were percentage changes from baseline in triglyceride (TG) and APOC-III levels at 24 weeks and the end of the study. Secondary outcomes included changes in other lipid parameters and safety outcomes at 24 weeks and the end of the study. A protocol was registered to PROSPERO under registration number [CRD420251026605].<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Four studies encompassing 1,514 participants were included in our meta-analysis. Plozasiran significantly improved TGs, APOC-III, non-high-density lipoprotein cholesterol (non-HDL-C), high-density lipoprotein cholesterol (HDL-C), and apolipoprotein B (ApoB) levels at both 24 weeks and study completion. Subgroup analyses based on dose and regimen revealed consistent findings. Quarterly administration of plozasiran at 10\u00a0mg, 25\u00a0mg, and 50\u00a0mg resulted in significant reductions in TGs, APOC-III, non\u2013HDL-C, and HDL-C at both 24 weeks and study completion. For ApoB, all three doses produced significant reductions at 24 weeks; however, only the 25\u00a0mg and 50\u00a0mg quarterly regimens sustained these reductions through the end of the study. Regarding safety, patients receiving plozasiran experienced a higher incidence of any adverse events, headache, and mild rises in HbA1C levels. Subgroup analysis revealed a dose-dependent pattern for certain safety outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>While Plozasiran shows strong potential as a therapeutic option for severe dyslipidemic conditions, further studies are needed to compare its efficacy and safety with currently available treatments and, more importantly, evaluate its impact on clinical outcomes for implementation in clinical practice.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10557-025-07798-8","type":"journal-article","created":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T08:55:01Z","timestamp":1763456101000},"page":"1085-1106","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["The Efficacy and Safety of Plozasiran on Lipid Profile in Dyslipidemic Disorders: A Systematic Review and Meta-Analysis"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4435-544X","authenticated-orcid":false,"given":"Pishoy","family":"Sydhom","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9649-9712","authenticated-orcid":false,"given":"Bakr","family":"Al-Quraishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-0906-0368","authenticated-orcid":false,"given":"Aya","family":"Gohar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-4189-0975","authenticated-orcid":false,"given":"Mohamad","family":"El-Shawaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8574-3289","authenticated-orcid":false,"given":"Nahla","family":"Shehata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7406-104X","authenticated-orcid":false,"given":"Miral","family":"Ataya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-5473-9614","authenticated-orcid":false,"given":"Mark","family":"Sydhom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-3700-4864","authenticated-orcid":false,"given":"Nouran","family":"Awwad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-8774-8254","authenticated-orcid":false,"given":"Haidy","family":"Motawade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-8648-8269","authenticated-orcid":false,"given":"Nourhan","family":"Naji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7325-0129","authenticated-orcid":false,"given":"Mahmoud Shaaban","family":"Abdelgalil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,18]]},"reference":[{"issue":"4","key":"7798_CR1","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1210\/endrev\/bnab037","volume":"43","author":"AJ Berberich","year":"2022","unstructured":"Berberich AJ, Hegele RA. A modern approach to dyslipidemia. Endocr Rev. 2022;43(4):611\u201353. https:\/\/doi.org\/10.1210\/endrev\/bnab037.","journal-title":"Endocr Rev"},{"key":"7798_CR2","doi-asserted-by":"publisher","unstructured":"Badimon L, Chiva-Blanch G. Lipid metabolism in dyslipidemia and familial hypercholesterolemia. InThe molecular nutrition of fats 2019 Jan 1 (pp. 307-322). Academic Press. https:\/\/doi.org\/10.1016\/B978-0-12-811297-7.00024-X","DOI":"10.1016\/B978-0-12-811297-7.00024-X"},{"key":"7798_CR3","doi-asserted-by":"crossref","unstructured":"Carroll MD, Kit BK, Lacher DA, Shero ST, Mussolino ME. Trends in Lipids and Lipoproteins in US Adults, 1988\u20132010. JAMA [Internet]. 2012 Oct 17 [cited 2025 Apr 16];308(15):1545\u201354. Available from: https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/1383233.","DOI":"10.1001\/jama.2012.13260"},{"issue":"6","key":"7798_CR4","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.artere.2020.11.002","volume":"32","author":"A Ruiz-Garc\u00eda","year":"2020","unstructured":"Ruiz-Garc\u00eda A, Arranz-Mart\u00ednez E, L\u00f3pez-Uriarte B, et al. Prevalence of hypertriglyceridemia in adults and related cardiometabolic factors. SIMETAP-HTG study. Cl\u00ednica e Investigaci\u00f3n en Arteriosclerosis (English Edition). 2020;32(6):242\u201355.","journal-title":"Cl\u00ednica e Investigaci\u00f3n en Arteriosclerosis (English Edition)"},{"issue":"8","key":"7798_CR5","doi-asserted-by":"publisher","first-page":"756","DOI":"10.4158\/EP-2018-0157","volume":"24","author":"JM Falko","year":"2018","unstructured":"Falko JM. Familial chylomicronemia syndrome: A clinical guide for endocrinologists. Endocr Pract. 2018;24(8):756\u201363.","journal-title":"Endocr Pract"},{"key":"7798_CR6","doi-asserted-by":"publisher","unstructured":"Austin MA, McKnight B, Edwards KL, et al. Cardiovascular disease mortality in familial forms of hypertriglyceridemia: a 20-year prospective study. Circulation. 2000;101(24):2777\u201382. https:\/\/doi.org\/10.1161\/01.CIR.101.24.2777","DOI":"10.1161\/01.CIR.101.24.2777"},{"issue":"4","key":"7798_CR7","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1161\/CIRCRESAHA.115.306249","volume":"118","author":"BG Nordestgaard","year":"2016","unstructured":"Nordestgaard BG. Triglyceride-rich lipoproteins and atherosclerotic cardiovascular disease. Circ Res. 2016;118(4):547\u201363. https:\/\/doi.org\/10.1161\/CIRCRESAHA.115.306249.","journal-title":"Circ Res"},{"issue":"1","key":"7798_CR8","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1093\/eurheartj\/ehz785","volume":"41","author":"U Laufs","year":"2020","unstructured":"Laufs U, Parhofer KG, Ginsberg HN, Hegele RA. Clinical review on triglycerides. Eur Heart J. 2020;41(1):99\u2013109c. https:\/\/doi.org\/10.1093\/eurheartj\/ehz785.","journal-title":"Eur Heart J"},{"issue":"32","key":"7798_CR9","doi-asserted-by":"publisher","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","volume":"38","author":"BA Ference","year":"2017","unstructured":"Ference BA, Ginsberg HN, Graham I, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017;38(32):2459\u201372. https:\/\/doi.org\/10.1093\/eurheartj\/ehx144.","journal-title":"Eur Heart J"},{"key":"7798_CR10","doi-asserted-by":"publisher","unstructured":"Stone NJ, Robinson JG, Lichtenstein AH et al. 2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: A report of the american college of cardiology\/american heart association task force on practice guidelines. Circulation [Internet]. 2014 Jun 24 [cited 2025 Apr 16];129(25 SUPPL. 1):1\u201345. Available from: https:\/\/www.ahajournals.org\/doi\/https:\/\/doi.org\/10.1161\/01.cir.0000437738.63853.7a.","DOI":"10.1161\/01.cir.0000437738.63853.7a"},{"key":"7798_CR11","doi-asserted-by":"crossref","unstructured":"Pejic RN, Lee DT, Hypertriglyceridemia. The Journal of the American Board of Family Medicine [Internet]. 2006 May 1 [cited 2025 Apr 16];19(3):310\u20136. Available from: https:\/\/www.jabfm.org\/content\/19\/3\/310.","DOI":"10.3122\/jabfm.19.3.310"},{"key":"7798_CR12","doi-asserted-by":"crossref","unstructured":"Hegele RA, Ginsberg HN, Chapman MJ et al. The polygenic nature of hypertriglyceridaemia: Implications for definition, diagnosis, and management. Lancet Diabetes Endocrinol [Internet]. 2014 Aug 1 [cited 2025 Apr 16];2(8):655\u201366. Available from: https:\/\/www.thelancet.com\/action\/showFullText?pii=S2213858713701918.","DOI":"10.1016\/S2213-8587(13)70191-8"},{"key":"7798_CR13","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.atherosclerosissup.2017.05.003","volume":"30","author":"I Gouni-Berthold","year":"2017","unstructured":"Gouni-Berthold I. The role of antisense oligonucleotide therapy against apolipoprotein-CIII in hypertriglyceridemia. Atherosclerosis Suppl. 2017;30:19\u201327.","journal-title":"Atherosclerosis Suppl"},{"issue":"2","key":"7798_CR14","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1002\/path.2993","volume":"226","author":"JK Watts","year":"2012","unstructured":"Watts JK, Corey DR. Silencing disease genes in the laboratory and the clinic. J Pathol. 2012;226(2):365\u201379. https:\/\/doi.org\/10.1002\/path.2993.","journal-title":"J Pathol"},{"issue":"23","key":"7798_CR15","doi-asserted-by":"publisher","first-page":"2200","DOI":"10.1056\/NEJMoa1400284","volume":"371","author":"D Gaudet","year":"2014","unstructured":"Gaudet D, Brisson D, Tremblay K, et al. Targeting APOC3 in the familial chylomicronemia syndrome. N Engl J Med. 2014;371(23):2200\u20136. https:\/\/doi.org\/10.1056\/NEJMoa1400284.","journal-title":"N Engl J Med"},{"key":"7798_CR16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2404143","author":"CM Ballantyne","year":"2024","unstructured":"Ballantyne CM, Vasas S, Azizad M, et al. Plozasiran, an RNA interference agent targeting APOC3, for mixed hyperlipidemia. N Engl J Med. 2024. https:\/\/doi.org\/10.1056\/NEJMoa2404143.","journal-title":"N Engl J Med"},{"key":"7798_CR17","doi-asserted-by":"publisher","unstructured":"Watts GF, Rosenson RS, Hegele RA et al. Plozasiran for managing persistent chylomicronemia and pancreatitis risk. New Engl J Med [Internet]. 2024 Jan 9 [cited 2025 Apr 16]; Available from: https:\/\/www.nejm.org\/doi\/abs\/https:\/\/doi.org\/10.1056\/NEJMoa2409368.","DOI":"10.1056\/NEJMoa2409368"},{"key":"7798_CR18","doi-asserted-by":"crossref","unstructured":"Page MJ, McKenzie JE, Bossuyt PM et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ [Internet]. 2021 Mar 29 [cited 2025 Apr 16];372. Available from: https:\/\/www.bmj.com\/content\/372\/bmj.n71.","DOI":"10.1136\/bmj.n71"},{"key":"7798_CR19","unstructured":"Higgins JPT, Thomas J, Chandler J, Cochrane handbook for systematic reviews of interventions IF: NA NA NA. dariososafoula.wordpress.comJ Chandler, Cumpston M, Li T, Page MJ et al. V WelchHoboken: Wiley, 2019\u2022dariososafoula.wordpress.com [Internet]. 2019 [cited 2025 Apr 16]; Available from: https:\/\/dariososafoula.wordpress.com\/wp-content\/uploads\/2017\/01\/cochrane-handbook-for-systematic-reviews-of-interventions-2019-1.pdf."},{"issue":"1","key":"7798_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/s12874-024-02356-6","volume":"24","author":"A Abbas","year":"2024","unstructured":"Abbas A, Hefnawy MT, Negida A. Meta-analysis accelerator: a comprehensive tool for statistical data conversion in systematic reviews with meta-analysis. BMC Med Res Methodol. 2024;24(1):243.","journal-title":"BMC Med Res Methodol"},{"key":"7798_CR21","doi-asserted-by":"crossref","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ [Internet]. 2019 Aug 28 [cited 2025 Apr 16];366. Available from: https:\/\/www.bmj.com\/content\/366\/bmj.l4898.","DOI":"10.1136\/bmj.l4898"},{"key":"7798_CR22","doi-asserted-by":"publisher","unstructured":"Gaudet D, Clifton P, Sullivan D et al. RNA Interference Therapy Targeting Apolipoprotein C-III in Hypertriglyceridemia. NEJM Evidence [Internet]. 2023 Nov 17 [cited 2025 Apr 16];2(12). Available from: https:\/\/evidence.nejm.org\/doi\/full\/https:\/\/doi.org\/10.1056\/EVIDoa2200325.","DOI":"10.1056\/EVIDoa2200325"},{"key":"7798_CR23","doi-asserted-by":"crossref","unstructured":"Gaudet D, Pall D, Watts GF et al. Plozasiran (ARO-APOC3) for Severe Hypertriglyceridemia: The SHASTA-2 Randomized Clinical Trial. JAMA Cardiol [Internet]. 2024 Jul 1 [cited 2025 Apr 16];9(7):620\u201330. Available from: https:\/\/jamanetwork.com\/journals\/jamacardiology\/fullarticle\/2817469.","DOI":"10.1001\/jamacardio.2024.0959"},{"key":"7798_CR24","doi-asserted-by":"crossref","unstructured":"Sacks FM. The crucial roles of apolipoproteins E and C-III in apoB lipoprotein metabolism in normolipidemia and hypertriglyceridemia. Curr Opin Lipidol [Internet]. 2015 Feb 13 [cited 2025 Apr 16];26(1):56\u201363. Available from: https:\/\/journals.lww.com\/co-lipidology\/fulltext\/2015\/02000\/the_crucial_roles_of_apolipoproteins_e_and_c_iii.10.aspx.","DOI":"10.1097\/MOL.0000000000000146"},{"issue":"15","key":"7798_CR25","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1161\/CIRCULATIONAHA.109.875807","volume":"121","author":"C Zheng","year":"2010","unstructured":"Zheng C, Khoo C, Furtado J, Sacks FM. Apolipoprotein C-III and the metabolic basis for hypertriglyceridemia and the dense low-density lipoprotein phenotype. Circulation. 2010;121(15):1722\u201334. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.109.875807.","journal-title":"Circulation"},{"issue":"5","key":"7798_CR26","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1194\/jlr.P600011-JLR200","volume":"48","author":"C Zheng","year":"2007","unstructured":"Zheng C, Khoo C, Ikewaki K, Sacks FM. Rapid turnover of apolipoprotein C-III-containing triglyceride-rich lipoproteins contributing to the formation of LDL subfractions. J Lipid Res. 2007;48(5):1190\u2013203.","journal-title":"J Lipid Res"},{"issue":"2","key":"7798_CR27","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1161\/ATVBAHA.109.197830","volume":"30","author":"CO Mendivil","year":"2010","unstructured":"Mendivil CO, Zheng C, Furtado J, Lel J, Sacks FM. Metabolism of very-low-density lipoprotein and low-density lipoprotein containing apolipoprotein C-III and not other small apolipoproteins. Arterioscler Thromb Vasc Biol. 2010;30(2):239\u201345. https:\/\/doi.org\/10.1161\/ATVBAHA.109.197830.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"5","key":"7798_CR28","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1161\/CIRCULATIONAHA.105.591743","volume":"113","author":"A Kawakami","year":"2006","unstructured":"Kawakami A, Aikawa M, Libby P, et al. Apolipoprotein CIII in apolipoprotein B lipoproteins enhances the adhesion of human monocytic cells to endothelial cells. Circulation. 2006;113(5):691\u2013700. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.105.591743.","journal-title":"Circulation"},{"issue":"7","key":"7798_CR29","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1161\/CIRCULATIONAHA.106.622514","volume":"114","author":"A Kawakami","year":"2006","unstructured":"Kawakami A, Aikawa M, Alcaide P, et al. Apolipoprotein CIII induces expression of vascular cell adhesion molecule-1 in vascular endothelial cells and increases adhesion of monocytic cells. Circulation. 2006;114(7):681\u20137. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.106.622514.","journal-title":"Circulation"},{"issue":"19","key":"7798_CR30","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1161\/CIRCULATIONAHA.111.056986","volume":"124","author":"CO Mendivil","year":"2011","unstructured":"Mendivil CO, Rimm EB, Furtado J, Chiuve SE, Sacks FM. Low-density lipoproteins containing apolipoprotein C-III and the risk of coronary heart disease. Circulation. 2011;124(19):2065\u201372. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.111.056986.","journal-title":"Circulation"},{"key":"7798_CR31","doi-asserted-by":"crossref","unstructured":"Ooi EMM, Barrett PHR, Chan DC, Watts GF. Apolipoprotein C-III: understanding an emerging cardiovascular risk factor. Clin Sci [Internet]. 2008 May 1 [cited 2025 Apr 16];114(10):611\u201324. Available from: \/clinsci\/article\/114\/10\/611\/68347\/Apolipoprotein-C-III-understanding-an-emerging.","DOI":"10.1042\/CS20070308"},{"key":"7798_CR32","doi-asserted-by":"crossref","unstructured":"Loss-of-Function Mutations in APOC3, Triglycerides, and Coronary Disease . New England Journal of Medicine [Internet]. 2014 Jul 3 [cited 2025 Apr 16];371(1):22\u201331. Available from:\u00a0https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa1307095","DOI":"10.1056\/NEJMoa1307095"},{"issue":"1","key":"7798_CR33","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","volume":"41","author":"F Mach","year":"2019","unstructured":"J\u00f8rgensen AB, Frikke-Schmidt R, Nordestgaard BG, Tybj\u00e6rg-Hansen A. Loss-of-Function Mutations in APOC3 and Risk of Ischemic Vascular Disease . New England Journal of Medicine [Internet]. 2014 Jul 3 [cited 2025 Apr 16];371(1):32\u201341. Available from: https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa1308027","journal-title":"Eur Heart J"},{"key":"7798_CR34","unstructured":"Mirbolouk M, Med MBCCJ, 2020 undefined. ACC\/AHA lipid guidelines: personalized care to prevent cardiovascular disease IF: NA NA NA. researchgate.netM Mirbolouk, MJ BlahaCleve Clin J Med, 2020\u2022researchgate.net [Internet]. [cited 2025 Apr 16]; Available from: https:\/\/www.researchgate.net\/profile\/Cara-Reiter-Brennan\/publication\/340371888_ACCAHA_lipid_guidelines_Personalized_care_to_prevent_cardiovascular_disease\/links\/5ecbafcda6fdcc90d69753c3\/ACC-AHA-lipid-guidelines-Personalized-care-to-prevent-cardiovascular-disease.pdf"},{"key":"7798_CR35","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2020.00455","volume":"11","author":"JS Dron","year":"2020","unstructured":"Mach F, Baigent C, Catapano AL, et al. 2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). Eur Heart J [Internet]. 2020 Jan 1 [cited 2025 Apr 16];41(1):111\u201388. Available from: https:\/\/dx.doi.org\/10.1093\/eurheartj\/ehz455","journal-title":"Front Endocrinol (Lausanne)"},{"key":"7798_CR36","doi-asserted-by":"crossref","unstructured":"Baass A, Paquette M, Bernard S, Hegele RA. Familial chylomicronemia syndrome: an under-recognized cause of severe hypertriglyceridaemia. J Intern Med [Internet]. 2020 Apr 1 [cited 2025 Apr 16];287(4):340\u20138. Available from: https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1111\/joim.13016","DOI":"10.1111\/joim.13016"},{"key":"7798_CR37","doi-asserted-by":"crossref","unstructured":"Dron JS, Hegele RA. Genetics of Hypertriglyceridemia. Front Endocrinol (Lausanne). 2020 Jul 24;11:538521.","DOI":"10.3389\/fendo.2020.00455"},{"key":"7798_CR38","doi-asserted-by":"crossref","unstructured":"Hansen MK, Mortensen MB, Warnakula Olesen KK, Thrane PG, Maeng M. Non-HDL cholesterol and residual risk of cardiovascular events in patients with ischemic heart disease and well-controlled LDL cholesterol: a cohort study. The Lancet Regional Health - Europe [Internet]. 2024 Jan 1 [cited 2025 Apr 16];36. Available from: https:\/\/www.thelancet.com\/action\/showFullText?pii=S266677622300193X","DOI":"10.1016\/j.lanepe.2023.100774"},{"key":"7798_CR39","doi-asserted-by":"crossref","unstructured":"Johannesen CDL, Mortensen MB, Langsted A, Nordestgaard BG. Apolipoprotein B and Non-HDL Cholesterol Better Reflect Residual Risk Than LDL Cholesterol in Statin-Treated Patients. J Am Coll Cardiol [Internet]. 2021 Mar 23 [cited 2025 Apr 16];77(11):1439\u201350. Available from: https:\/\/www.jacc.org\/doi\/10.1016\/j.jacc.2021.01.027","DOI":"10.1016\/j.jacc.2021.01.027"},{"key":"7798_CR40","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.atherosclerosis.2023.05.008","volume":"375","author":"A Jones","year":"2023","unstructured":"Tall AR, Thomas DG, Gonzalez-Cabodevilla AG, Goldberg IJ. Addressing dyslipidemic risk beyond LDL-cholesterol. J Clin Invest [Internet]. 2022 Jan 4 [cited 2025 Apr 16];132(1). Available from: https:\/\/doi.org\/10.1172\/JCI148559","journal-title":"Atherosclerosis"},{"key":"7798_CR41","doi-asserted-by":"crossref","unstructured":"Gouni-Berthold I, Alexander VJ, Yang Q, et al. Efficacy and safety of volanesorsen in patients with multifactorial chylomicronaemia (COMPASS): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol [Internet]. 2021 May 1 [cited 2025 Apr 16];9(5):264\u201375. Available from: https:\/\/www.thelancet.com\/action\/showFullText?pii=S2213858721000462","DOI":"10.1016\/S2213-8587(21)00046-2"},{"key":"7798_CR42","doi-asserted-by":"crossref","unstructured":"Jones A, Peers K, Wierzbicki AS, et al. Long-term effects of volanesorsen on triglycerides and pancreatitis in patients with familial chylomicronaemia syndrome (FCS) in the UK Early Access to Medicines Scheme (EAMS). Atherosclerosis. 2023 Jun 1;375:67\u201374.","DOI":"10.1016\/j.atherosclerosis.2023.05.008"},{"key":"7798_CR43","doi-asserted-by":"crossref","unstructured":"Tardif JC, Investigators for the OS, Karwatowska-Prokopczuk E, Investigators for the OS, Amour ES, Investigators for the OS, et al. Apolipoprotein C-III reduction in subjects with moderate hypertriglyceridaemia and at high cardiovascular risk. Eur Heart J [Internet]. 2022 Apr 6 [cited 2025 Apr 16];43(14):1401\u201312. Available from: https:\/\/dx.doi.org\/10.1093\/eurheartj\/ehab820","DOI":"10.1093\/eurheartj\/ehab820"},{"key":"7798_CR44","doi-asserted-by":"publisher","unstructured":"Chen C, Wei FF, Dong Y, et al. Early Management of Blood Lipid Levels with Non-Statin Lipid-Lowering Drugs in Acute Coronary Syndrome: A Mini Review. Cardiovasc Drugs Ther (2024). https:\/\/doi.org\/10.1007\/s10557-024-07587-9","DOI":"10.1007\/s10557-024-07587-9"},{"key":"7798_CR45","doi-asserted-by":"publisher","DOI":"10.1007\/s10557-023-07519-z","author":"H Sabbour","year":"2024","unstructured":"Sabbour H, Bhatt DL, Elhenawi Y, et al. A Practical Approach to the Management of Residual Cardiovascular Risk: United Arab Emirates Expert Consensus Panel on the Evidence for Icosapent Ethyl and Omega-3 Fatty Acids. Cardiovasc Drugs Ther. 2024. https:\/\/doi.org\/10.1007\/s10557-023-07519-z.","journal-title":"Cardiovasc Drugs Ther"}],"container-title":["Cardiovascular Drugs and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-025-07798-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10557-025-07798-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-025-07798-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T05:21:44Z","timestamp":1778649704000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10557-025-07798-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,18]]},"references-count":45,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["7798"],"URL":"https:\/\/doi.org\/10.1007\/s10557-025-07798-8","relation":{},"ISSN":["0920-3206","1573-7241"],"issn-type":[{"value":"0920-3206","type":"print"},{"value":"1573-7241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,18]]},"assertion":[{"value":"10 October 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"All authors declared no conflict of interest.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}